Neo Ivy Capital Management Buys Shares of 93,260 The Chemours Company $CC

Neo Ivy Capital Management purchased a new position in shares of The Chemours Company (NYSE:CC) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 93,260 shares of the specialty chemicals company’s stock, valued at approximately $1,477,000. Neo Ivy Capital Management owned 0.06% of Chemours at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. MTM Investment Management LLC bought a new position in Chemours during the 2nd quarter worth $27,000. Evelyn Partners Asset Management Ltd bought a new stake in Chemours in the second quarter valued at $37,000. Hantz Financial Services Inc. lifted its stake in Chemours by 334.2% in the third quarter. Hantz Financial Services Inc. now owns 4,329 shares of the specialty chemicals company’s stock valued at $69,000 after buying an additional 3,332 shares during the last quarter. Itau Unibanco Holding S.A. boosted its holdings in shares of Chemours by 102.3% during the second quarter. Itau Unibanco Holding S.A. now owns 7,149 shares of the specialty chemicals company’s stock valued at $82,000 after acquiring an additional 3,615 shares during the period. Finally, CWM LLC boosted its holdings in shares of Chemours by 32.4% during the third quarter. CWM LLC now owns 5,682 shares of the specialty chemicals company’s stock valued at $90,000 after acquiring an additional 1,392 shares during the period. Institutional investors own 76.26% of the company’s stock.

Analyst Upgrades and Downgrades

CC has been the topic of a number of analyst reports. UBS Group increased their price objective on shares of Chemours from $18.00 to $23.00 and gave the stock a “buy” rating in a report on Monday, February 23rd. BMO Capital Markets decreased their target price on shares of Chemours from $20.00 to $19.00 and set an “outperform” rating for the company in a research report on Monday, February 23rd. JPMorgan Chase & Co. raised their price target on shares of Chemours from $13.00 to $17.00 and gave the company a “neutral” rating in a research note on Monday, February 23rd. Jefferies Financial Group reaffirmed a “hold” rating and set a $17.00 price target on shares of Chemours in a report on Monday, February 23rd. Finally, Royal Bank Of Canada reiterated an “outperform” rating and set a $18.00 price objective on shares of Chemours in a research report on Friday, January 16th. Five research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $18.40.

Chemours Trading Down 1.9%

Shares of Chemours stock opened at $16.44 on Friday. The company has a quick ratio of 0.85, a current ratio of 1.78 and a debt-to-equity ratio of 16.33. The firm has a market cap of $2.47 billion, a price-to-earnings ratio of -6.63 and a beta of 1.60. The business has a fifty day simple moving average of $16.38 and a 200-day simple moving average of $14.74. The Chemours Company has a fifty-two week low of $9.13 and a fifty-two week high of $21.85.

Chemours (NYSE:CC) last released its earnings results on Thursday, February 19th. The specialty chemicals company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.04. Chemours had a positive return on equity of 41.75% and a negative net margin of 6.41%.The firm had revenue of $1.33 billion for the quarter, compared to analyst estimates of $1.33 billion. During the same period in the previous year, the company earned $0.09 earnings per share. Chemours’s revenue was down 2.2% compared to the same quarter last year. On average, equities analysts forecast that The Chemours Company will post 2.03 EPS for the current fiscal year.

Chemours Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 13th. Stockholders of record on Friday, February 27th will be paid a $0.0875 dividend. The ex-dividend date of this dividend is Friday, February 27th. This represents a $0.35 annualized dividend and a dividend yield of 2.1%. Chemours’s payout ratio is currently -14.11%.

Key Headlines Impacting Chemours

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Mizuho raised its price target on Chemours to $21.00 and maintained an “outperform” rating, signaling analyst confidence in upside potential versus the current price. Benzinga Coverage
• Neutral Sentiment: Zacks Research published a FY2028 EPS projection of $2.50 for Chemours — a longer-term estimate that could be constructive if later quarters show recovery, but it comes alongside multiple near-term downgrades. MarketBeat: CC
• Negative Sentiment: Zacks cut several near-term earnings forecasts across 2026–2027: Q1 2026 to ($0.09) from $0.20, Q2 2026 to $0.60 from $0.69, Q3 2026 to $0.42 from $0.57, Q4 2026 to $0.13 from $0.29, FY2026 to $1.06 from $1.75, and FY2027 to $1.97 from $2.30. These downward revisions signal weaker expected near-term profitability and are likely weighing on the stock. MarketBeat: Zacks Revisions
• Negative Sentiment: Pomerantz LLP announced an investor investigation into Chemours, which introduces legal/settlement risk and can increase volatility and investor concern until clarity emerges. PR Newswire: Pomerantz Investigation

Chemours Profile

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.